PuSH - Publication Server of Helmholtz Zentrum München

Piseddu, I.* ; Endres, R.* ; Lanzl, F.* ; Hammann, L.* ; Bérouti, M.* ; Thaler, M.* ; Fahr, L.* ; Fischer, H.* ; Varlamova, V.* ; Gärtig, J.* ; Nixdorf, D.* ; Layritz, P.* ; Marx, C.* ; Hörth, C.* ; Witte, C.* ; Bulut, A.* ; Illig, D.* ; Senz, A.M.* ; Holdt, L.* ; Regel, I.* ; Gottschlich, A.* ; Subklewe, M.* ; Mayerle, J.* ; Anz, D.* ; Kobold, S. ; Linder, A.* ; Hornung, V.*

STING ablation in T cells is required for the efficacy of STING agonists in CAR-T cell immunotherapy of pancreatic cancer.

Gastroenterology, DOI: 10.1053/j.gastro.2026.01.031 (2026)
DOI PMC
BACKGROUND & AIMS: Chimeric antigen receptor (CAR) T cells have shown great potential in hematological cancers, but lack efficacy in solid tumors, highlighting the need for novel strategies. STING activation was shown to inflame the tumor microenvironment, but combination of STING agonists and CAR-T cells might be limited by detrimental outcomes of T cell-intrinsic STING activation. In this study, we evaluated the potential of combining STING agonists and CAR-T cells in the context of pancreatic cancer METHODS: We assessed the synergy of CRISPR-Cas9-edited CAR-T cells and the STING agonist diABZI within a T cell exhaustion model in vitro and both xenograft and syngeneic mouse models in vivo. RESULTS: Combination of STING-ablated CAR-T cells and diABZI resulted in enhanced cancer cell killing, increased CAR-T cell proliferation, reduced exhaustion and expansion of an effector-memory phenotype in vitro. Mechanistically, superior CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling upon STING-agonistic treatment. Moreover, we identified a synergistic feedback loop comprising the T cell-secreted cytokines IFN-γ and TNF, which prime STING signaling within cancer cells, thereby potentiating the outcomes of cancer cell-intrinsic STING activation in inducing ameliorated CAR-T cell states. Ultimately, we could demonstrate that combination of STINGKO CAR-T cells and diABZI was able to provide enhanced tumor control in both xenograft and syngeneic mouse models. This was accompanied by increased intratumoral CAR-T cell numbers and reprogramming of the tumor microenvironment in vivo. CONCLUSION: Our findings suggest that STINGKO CAR-T cells stand to benefit from STING agonists to improve CAR-T cell therapy for immune-deprived cancers such as pancreatic cancer.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Car-t Cells ; Crispr-cas9 ; Pdac ; Sting
ISSN (print) / ISBN 0016-5085
e-ISSN 1528-0012
Journal Gastroenterology
Publisher Elsevier
Reviewing status Peer reviewed
Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)